leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...56789101112131415...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    A CASE OF CHEMOTHERAPY HYPERSENSITIVITY TO OXALIPLATIN AND LEUCOVORIN (Monitor 1; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_999;    
    This case highlights an exceptionally rare instance of oxaliplatin and leucovorin IDRs, confirmed through patient history and skin testing. Intradermal Skin Testing Results
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    DESENSITIZATION TO RAMUCIRUMAB IN SIGNET-CELL GASTRIC ADENOCARCINOMA (Monitor 1; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_690;    
    After anaphylaxis management with epinephrine and hydrocortisone a desensitization protocol (3-bag, 12-steps) was proposed and performed successfully with its proper premedication (dexamethasone, diphenhydramine, fosaprepitant and palonosetron) every 3 weeks without HSR for 4 cycles...Table 1. 3-Bags, 12-Steps Desensitization protocol to Ramucirumab.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    P2 data, Journal:  mFOLFOX6 versus mFOLFOX6 (Pubmed Central) -  Sep 28, 2024   
    3-Bags, 12-Steps Desensitization protocol to Ramucirumab. In patients with locally advanced rectal cancer and MRI-defined low risk of local recurrence, neoadjuvant mFOLFOX6
  • ||||||||||  leucovorin calcium / Generic mfg.
    Review, Journal, IO biomarker, Metastases:  Systemic Therapy for Metastatic Pancreatic Cancer-Current Landscape and Future Directions. (Pubmed Central) -  Sep 27, 2024   
    Kirsten Rat Sarcoma Virus (KRAS) G12D mutations are present in >90% of all PDAC's; exciting breakthroughs in small molecule inhibitors targeting KRAS G12D may open new modalities of treatment, and therapies targeting multiple KRAS mutations are also in early clinical trials. Although immunotherapy strategies to date have been disappointing, combination with chemotherapy and/or small molecule inhibitors hold promise and warrant further exploration.
  • ||||||||||  sirexatamab (DKN-01) / Leap Therap
    Enrollment closed, Metastases:  DeFianCe: Phase 2 Study of DKN-01 in Colorectal Cancer (clinicaltrials.gov) -  Sep 27, 2024   
    P2,  N=189, Active, not recruiting, 
    Prior IRI exposure was not a significant predictive factor for OS and PFS, especially in IRI responders. Recruiting --> Active, not recruiting
  • ||||||||||  irinotecan / Generic mfg.
    Journal, Metastases:  Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer. (Pubmed Central) -  Sep 26, 2024   
    We developed transcriptomic signatures for each drug of the mFFX regimen (5FU, oxaliplatin and irinotecan) by integrating transcriptomic data from PDC, PDO and PDX with their corresponding chemo-response profiles to capture the biological components responsible for the response to each drug...We then studied the response of patients to 0, 1, 2 and 3 drugs and we identified a positive correlation between the number of drugs predicted as sensitive and the OS and PFS, and the with objective response rate. We developed three novel transcriptome-based signatures which define sensitivity for each mFFX components that can be used to rationalize the administration of the mFFX regimen in patients with metastatic pancreatic cancer and could help to avoid unnecessary toxic effects.
  • ||||||||||  Trial primary completion date, Metastases:  Redefining FOLFIORINOX in Older Pancreatic Cancer Patients (clinicaltrials.gov) -  Sep 26, 2024   
    P2,  N=37, Recruiting, 
    We developed three novel transcriptome-based signatures which define sensitivity for each mFFX components that can be used to rationalize the administration of the mFFX regimen in patients with metastatic pancreatic cancer and could help to avoid unnecessary toxic effects. Trial primary completion date: Sep 2024 --> Sep 2025
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Use of Eculizumab in the Management of Drug-Induced Thrombotic Microangiopathy: A Case Report (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_4314;    
    Skin biopsy revealed +ve staining for C5b-9 in 8-10 dermal capillaries.Patient was started on Eculizumab 900mg on day 1.There was immediate improvement in hematological markers; however,sCr continued to rise upto 14 over next few days.She underwent a kidney biopsy(10 days after presentation),which revealed severe acute tubular injury with intraluminal material suggestive of hemoglobin casts,diffuse C5b-9 positivity, and focal subacute endothelial injury involving glomeruli with thickening of capillary walls.Patient continued to receive Eculizumab weekly then biweekly with sCr trending down to 1.0 over the course of a month. This case highlights the immediate reversal of microangiopathic hemolytic anemia with the use of Eculizumab.Early use of eculizumab likely reduced the severity of kidney injury and aided in the complete recovery of kidney function.
  • ||||||||||  botensilimab (AGEN1181) / Agenus, balstilimab (AGEN2034) / Agenus
    Trial initiation date:  BBOpCo: Botensilimab and Balstilimab Optimization in Colorectal Cancer (clinicaltrials.gov) -  Sep 20, 2024   
    P2,  N=15, Not yet recruiting, 
    N=1638 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Jul 2024 --> Oct 2024
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment closed, Trial primary completion date, Metastases:  TRIBE-C: Bevacizumab Plus MFOLFOXIRI As First-line Treatment for Patients with Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) -  Sep 20, 2024   
    P3,  N=528, Active, not recruiting, 
    A 5-fluorouracil- or gemcitabine-based combined regimen was shown to be as effective as a single 5-fluorouracil or gemcitabine regimen as second-line therapy for patients with APC. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2024 --> Jan 2024